Oxford BioDynamics PLC Results of General Meeting (1099S)
November 11 2021 - 6:08AM
UK Regulatory
TIDMOBD
RNS Number : 1099S
Oxford BioDynamics PLC
11 November 2021
11 November 2021
Oxford Biodynamics Plc
Results of General Meeting
Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology
company developing targeted clinical diagnostic tests for immune
health using its EpiSwitch(R) 3D genomics technology, announces
that both resolutions proposed at the Company's General Meeting,
held earlier today, were duly passed. Holders of 63,233,927 shares
(representing 63% of the issued share capital of the Company)
submitted proxy votes. Over 99% of the votes cast were in favour of
each of the resolutions. Accordingly, warrants to subscribe for
7,791,803 new ordinary shares at an exercise price of 58.125 pence
per new Ordinary Share have been issued to Armistice Capital Master
Fund Limited.
-ENDS-
For further details please contact:
Oxford BioDynamics Plc Tel: +44 (0)1865 518910
Jon Burrows, CEO
Paul Stockdale, CFO
Shore Capital - Nominated Adviser and Tel: +44 (0)20 7408 4090
Broker
Advisory: Stephane Auton / John More
Broking: Fiona Conroy
Instinctif Partners Tel: +44 (0)20 7457 2020
Melanie Toyne-Sewell / Nathan Billis OxfordBioDynamics@instinctif.com
NOTES TO EDITORS:
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology
company, advancing personalized healthcare by developing and
commercializing precision medicine tests for life-changing
diseases.
In March 2021, the Company launched its first commercial
prognostic test, EpiSwitch (R) CST (Covid Severity Test) and the
first commercially available microarray kit for high-resolution 3D
genome profiling and biomarker discovery, EpiSwitch(R) Explorer
Array Kit . Its next product will be EpiSwitch(R) CiRT (Checkpoint
Inhibitor Response Test) for cancer, a predictive immune response
profile for immuno-oncology (IO) checkpoint inhibitor treatments,
to be launched later in 2021.
The Company has developed a proprietary 3D genomic biomarker
platform, EpiSwitch(R), which can build molecular diagnostic
classifiers for prediction of response to therapy, patient
prognosis, disease diagnosis and subtyping, and residual disease
monitoring in a wide range of indications.
Oxford BioDynamics has participated in more than 40 partnerships
with big pharma and leading institutions including Pfizer, EMD
Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts
General Hospital and Mitsubishi Tanabe Pharma.
The Company has created a valuable technology portfolio,
including biomarker arrays, molecular diagnostic tests,
bioinformatic tools for 3D genomics and an expertly curated 3D
genome knowledgebase comprising hundreds of millions of data points
from over 10,000 samples in more than 30 human diseases.
OBD is headquartered in Oxford, UK and is listed on AIM of the
London Stock Exchange. It also has a commercial office in
Gaithersburg, MD, USA and a reference laboratory in Penang,
Malaysia.
For more information, please visit the Company's website,
www.oxfordbiodynamics.com , or follow on Twitter or LinkedIn .
About EpiSwitch(R)
The 3D configuration of the genome plays a crucial role in gene
regulation. By mapping this architecture and identifying abnormal
configurations, EpiSwitch(R) can be used to diagnose patients or
determine how individuals might respond to a disease or
treatment.
Built on over 10 years of research, EpiSwitch(R) is Oxford
Biodynamics' award-winning, proprietary platform that enables
screening, evaluation, validation and monitoring of 3D genomic
biomarkers. The technology is fully developed, based on testing of
over 10,000 samples in 30 disease areas, and reduced to
practice.
In addition to stratifying patients with respect to anticipated
clinical outcome, EpiSwitch(R) data offer insights into systems
biology and the physiological manifestation of disease that are
beyond the scope of other molecular modalities. The technology has
performed well in academic medical research settings and has been
validated through its integration in biomarker discovery and
clinical development with big pharma.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ROMFFLFFFFLBFBQ
(END) Dow Jones Newswires
November 11, 2021 06:08 ET (11:08 GMT)
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Apr 2023 to Apr 2024